ClinicalTrials.gg
RecruitingNCT07607275Updated Sep 30, 2026

Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension

A Phase 4 interventional study of Yufeng Ningxin tablets and Placebo in Hypertension and Essential (Primary) Hypertension, sponsored by Beijing Anzhen Hospital. Recruiting at 16 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Beijing Anzhen Hospital · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Sep 30, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 408 studies in Hypertension with a site in China — 123 open to participants now, 146 under way, 12 of them phase 3. Hypertension · China.

Planned enrollment
113th of 306
350 · median 255
Started
2026
with 36 others
Phase 4
76 of 408
13 open now
Primary completion
2027-12
later than 107 of 145 live
Registered
378th of 408
by date
Lead sponsor
7 of 408
Beijing Anzhen Hospital

Among the 408 studies in Hypertension with a site in China, this one is the 113th largest by planned enrollment of the 306 interventional ones that give a count, is one of 37 that started in 2026, is one of 76 in phase 4, reaches primary completion later than 107 of the 145 other live ones, and was the 378th registered.

Hypertension

6,120 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

123 of the 408 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:

117 more — sign in →

All 123 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 408 studies in Hypertension with a site in China, or all of them as a file.
02

Study summary

Yufeng Ningxin, a traditional Chinese medicine, has demonstrated potential antihypertensive effects in animal studies and small clinical trials, but has not yet been rigorously evaluated in large randomized clinical trials. Here, the investigators conducted a double-blind, randomized controlled trial to assess the efficacy and safety of Yufeng Ningxin tablets in patients with hypertension.

03

Conditions studied

  • Hypertension
  • Essential (Primary) Hypertension
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female participants aged 18-65 years;
  2. Newly diagnosed, untreated hypertension or treated hypertension with a seated systolic blood pressure of 140-159 mmHg and a daytime mean ambulatory systolic blood pressure ≥135 mmHg, following a ≥2-week washout of background antihypertensive medications;
  3. The patient is capable of understanding the study requirements, is willing and able to comply with study procedures, and has provided written .

Exclusion criteria

Exclusion Criteria:

  1. Secondary hypertension (including, but not limited to, renovascular hypertension, pheochromocytoma, primary aldosteronism, Cushing syndrome, aortic coarctation, or due to known history of moderate-to-severe obstructive sleep apnea);
  2. Orthostatic hypotension (symptomatic or asymptomatic);
  3. Participation in another hypertension-related clinical trial at enrollment or within 6 months prior;
  4. Currently taking, taken within 30 days prior to randomization, or anticipated to receive during the study treatment period any medication or herbal supplement known to significantly affect blood pressure (with the exception of medications for the treatment of essential hypertension). These drugs include, but are not limited to: organic nitrates, (excluding topical or inhaled corticosteroids), central nervous system stimulants (e.g., methylphenidate, dexmethylphenidate, amphetamines), estrogens, monoamine oxidase inhibitors, digitalis preparations, Chinese proprietary medicines (such as Tianma Gouteng Granules, Songling Xuemaikang Capsules, Yangxue Qingnao Granules), and herbal medicines (including Salvia miltiorrhiza, Uncaria rhynchophylla, Ginkgo biloba leaves, Prunella vulgaris, etc.);
  5. Users of prescription non-steroidal anti-inflammatory drugs (NSAIDs); initiation of, changes to, or discontinuation of sodium-glucose co-transporter (SGLT2) inhibitor therapy within 4 weeks prior to screening. Patients who were stably taking an SGLT2 inhibitor or low-dose aspirin (defined as ≤100mg per day) for at least 4 weeks prior to screening with no anticipated changes during the study are permitted;
  6. Severe hepatic or renal diseases ( >3 times the value, or end stage renal disease on dialysis, or \<30 mL/min/1.73 m2);
  7. Type 1 diabetes or poorly controlled type 2 diabetes (>9.0%);
  8. History of large atherosclerotic cerebral infarction or hemorrhagic stroke (not including lacunar infarction and [TIA]);
  9. Hospitalization for myocardial infarction within last 6 months; Coronary revascularization (PCI or CABG) within last 12 months; Planned for PCI or CABG in the next 6 months;
  10. Sustained atrial fibrillation or arrhythmias interfering with electronic BP measurement;
  11. class III-IV heart failure, or hospitalization for chronic heart failure exacerbation within the past 6 months;
  12. Severe valvular diseases; Potential for surgery or percutaneous valve replacement within the study period;
  13. Dilated cardiomyopathy, hypertrophic cardiomyopathy, rheumatic heart disease, or congenital heart disease;
  14. Other severe diseases that may affect participant enrollment or survival, such as or acquired immunodeficiency syndrome (AIDS);
  15. Cognitive impairment or severe neuropsychiatric comorbidities that render the patient incapable of providing ;
  16. Participants preparing for or under pregnancy and/or lactation;
  17. Frequent night-shift work, with primary working hours during nighttime (e.g., 8:00 PM to 8:00 AM);
  18. Other conditions deemed inappropriate for participation by the investigators.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
350 participants (estimated)

Study arms

  • Placebo comparator
    Control group

    Participants will receive a placebo matched to Yufeng Ningxin, taken as 5 tablets per dose, 3 times daily for 8 weeks.

    Drug: Placebo

  • Experimental
    Treatment group

    Participants will receive Yufeng Ningxin tablets (0.28 g per tablet), taken as 5 tablets per dose, 3 times daily for 8 weeks.

    Drug: Yufeng Ningxin tablets

Interventions

  • DrugYufeng Ningxin tablets

    Participants will receive Yufeng Ningxin tablets (0.28 g per tablet), taken as 5 tablets per dose, 3 times daily for 8 weeks.

  • DrugPlacebo

    Participants will receive a placebo matched to Yufeng Ningxin, taken as 5 tablets per dose, 3 times daily for 8 weeks.

06

What researchers measure

Primary outcomes

  1. Change from baseline in office SBP at Week 8

    Time frame: 8 weeks from treatment initiation.

Secondary outcomes

  1. Change from baseline in office DBP at Week 8

    Time frame: 8 weeks from treatment initiation.

  2. Change from baseline in mean 24-hour ambulatory SBP/DBP at Week 8

    Time frame: 8 weeks from treatment initiation.

  3. Change from baseline in mean daytime ambulatory SBP/DBP at Week 8

    Time frame: 8 weeks from treatment initiation.

  4. Change from baseline in mean nighttime ambulatory SBP/DBP at Week 8

    Time frame: 8 weeks from treatment initiation.

  5. Change from baseline in Headache Impact Test-6 (HIT-6) score at Week 8.

    The Headache Impact Test-6 (HIT-6), a 6-item questionnaire, will be used as part of the evaluation for headache symptoms to assess the impact of headaches on daily life. Each item is scored as 6 (never), 8 (rarely), 10 (sometimes), 11 (very often), or 13 (always) points. Total scores range from 36 to 78, with higher scores indicating a greater impact (worse outcome). The "change from baseline" is calculated as the score at Week 8 minus the score at baseline.

    Time frame: 8 weeks from treatment initiation.

  6. Change from baseline in Headache Disability Index (HDI) score at Week 8.

    The Headache Disability Index (HDI), a 25-item tool designed to assess the impact of headache on daily activities and emotional well-being, will be used as part of the evaluation for headache symptoms. Each item is scored as 4 (yes), 2 (sometimes), or 0 (no). The total score ranges from 0 to 100, where higher scores indicate greater headache-related disability (worse outcome). The "change from baseline" is calculated as the score at Week 8 minus the score at baseline.

    Time frame: 8 weeks from treatment initiation.

  7. Change from baseline in species-level relative abundance of gut microbiota assessed by metagenomic shotgun sequencing at Week 8

    The species-level relative abundance (%) of the gut microbiota will be analyzed using metagenomic shotgun sequencing of fecal samples.

    Time frame: 8 weeks from treatment initiation.

  8. Change from baseline in alpha-diversity of gut microbiota assessed by metagenomic shotgun sequencing at Week 8

    Alpha-diversity: Evaluated by the Shannon index to measure community richness and evenness.

    Time frame: 8 weeks from treatment initiation.

  9. Change from baseline in beta-diversity of gut microbiota assessed by metagenomic shotgun sequencing at Week 8.

    Beta-diversity: Evaluated by Bray-Curtis dissimilarity to assess structural differences between microbial communities.

    Time frame: 8 weeks from treatment initiation.

  10. Change from baseline in functional profile of gut microbiota assessed by metagenomic shotgun sequencing at Week 8.

    Functional profile: The characterization of gut microbial functions based on databases such as KEGG (Kyoto Encyclopedia of Genes and Genomes) and MetaCyc.

    Time frame: 8 weeks from treatment initiation.

  11. Change from baseline in plasma and fecal metabolomic profiles at Week 8

    Time frame: 8 weeks from treatment initiation.

  12. Change from baseline in total cholesterol concentration at Week 8.

    The serum concentration of total cholesterol (TC) will be measured in a certified clinical laboratory.

    Time frame: 8 weeks from treatment initiation.

  13. Change from baseline in triglycerides concentration at Week 8.

    The serum concentration of triglycerides (TG) will be measured in a certified clinical laboratory.

    Time frame: 8 weeks from treatment initiation.

  14. Change from baseline in low-density lipoprotein cholesterol concentration at Week 8.

    The serum concentration of low-density lipoprotein cholesterol (LDL-C) will be measured in a certified clinical laboratory.

    Time frame: 8 weeks from treatment initiation.

  15. Change from baseline in high-density lipoprotein cholesterol concentration at Week 8.

    The concentration of high-density lipoprotein cholesterol (HDL-C) will be measured in a certified clinical laboratory.

    Time frame: 8 weeks from treatment initiation.

  16. Change from baseline in the fasting blood glucose concentration at Week 8.

    This outcome measure assesses the change in the fasting blood glucose concentration. All assessments are performed in a certified clinical laboratory.

    Time frame: 8 weeks from treatment initiation.

  17. Incidence of a composite safety outcome (including all-cause mortality, hospitalizations, emergency visits, and adverse events) during the 8-week period.

    This composite outcome measure tracks the overall safety profile of the intervention. It is defined as the number of participants experiencing at least one of the following safety-related events: (1) all-cause mortality; (2) hospitalizations or emergency visits; (3) adverse events.

    Time frame: 8 weeks from treatment initiation.

07

Study locations

12 of 16 sites recruiting
  • Beijing Anzhen Hospital
    Beijing, China
    Recruiting
    • Jun Cai · Contactcaijun7879@126.com · +86-10-81992130
    • Jun Cai · Principal investigator
  • Chinese PLA General Hospital
    Beijing, China
    Recruiting
    • Zongbin Li, MD · Contact
    • Zongbin Li · Principal investigator
  • Fuwai Hospital, Chinese Academy of Medical Sciences
    Beijing, China
    Recruiting
    • Wenjun Ma · Contact
    • Wenjun Ma · Principal investigator
  • Peking University First Hospital
    Beijing, China
    Recruiting
    • Yan Zhang · Contact
    • Yan Zhang · Principal investigator
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, China
    Not yet recruiting
    • Jing Chang · Contact
    • Jing Chang · Principal investigator
  • The Second Affiliated Hospital of Dalian Medical University
    Dalian, China
    Recruiting
    • Yanchun Ding · Contact
    • Yanchun Ding · Principal investigator
  • Inner Mongolia People's Hospital
    Hohhot, China
    Not yet recruiting
    • Xinjun Guo · Contact
    • Xinjun Guo · Principal investigator
  • Longyan First Hospital
    Longyan, China
    Not yet recruiting
    • Wuyang Zheng · Contact
    • Wuyang Zheng · Principal investigator
  • Luohe Central Hospital
    Luohe, China
    Recruiting
    • Qiaotao Xie · Contact
    • Qiaotao Xie · Principal investigator
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, China
    Recruiting
    • Yifei Dong · Contact
    • Yifei Dong · Principal investigator
  • Jiangsu Province Hospital
    Nanjing, China
    Recruiting
    • Wei Sun · Contact
    • Wei Sun · Principal investigator
  • The Second Affiliated Hospital of Shantou University Medical College
    Shantou, China
    Recruiting
    • Youren Chen · Contact
    • Youren Chen · Principal investigator
  • First Hospital of Shanxi Medical University
    Taiyuan, China
    Recruiting
    • Juyan Zhang · Contact
    • Juyan zhang · Principal investigator
  • Tianjin Kanghui Hospital
    Tianjin, China
    Recruiting
    • Ning Yang · Contact
    • Ning Yang · Principal investigator
  • Renmin Hospital of Wuhan University
    Wuhan, China
    Not yet recruiting
    • Hongxin Xu · Contact
    • Hongxin Xu · Principal investigator
  • The First Affiliated Hospital of Xiamen University
    Xiamen, China
    Recruiting
    • Zhengrong Huang · Contact
    • Zhengrong Huang · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.

Of 126 non-industry phase 4 interventional studies under Hypertension, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's planned 18 months is below that.

Counting every sponsor, half of 161 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2026
First posted
May 26, 2026
StartActual
May 15, 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Jun 1, 2028
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites changed recruiting status (5 now recruiting)
Show 5 sites
  • Fuwai Hospital, Chinese Academy of Medical Sciences · Beijing, ChinaNot yet recruiting→Recruiting
  • Peking University First Hospital · Beijing, ChinaNot yet recruiting→Recruiting
  • Jiangsu Province Hospital · Nanjing, ChinaNot yet recruiting→Recruiting
  • The Second Affiliated Hospital of Shantou University Medical College · Shantou, ChinaNot yet recruiting→Recruiting
  • First Hospital of Shanxi Medical University · Taiyuan, ChinaNot yet recruiting→Recruiting
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    5 sites changed recruiting status (5 now recruiting)
    Show 5 sites
    • Fuwai Hospital, Chinese Academy of Medical Sciences · Beijing, ChinaNot yet recruiting→Recruiting
    • Peking University First Hospital · Beijing, ChinaNot yet recruiting→Recruiting
    • Jiangsu Province Hospital · Nanjing, ChinaNot yet recruiting→Recruiting
    • The Second Affiliated Hospital of Shantou University Medical College · Shantou, ChinaNot yet recruiting→Recruiting
    • First Hospital of Shanxi Medical University · Taiyuan, ChinaNot yet recruiting→Recruiting
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07607275
Responsible party
Jun Cai (Director, Head of Hypertension Center, Principal Investigator, Clinical Professor, Beijing Anzhen Hospital) — Principal investigator
First posted
May 26, 2026
Start date
May 15, 2026
Primary completion
Dec 1, 2027 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Sep 30, 2026

Study contacts

Ruixue Yang, MD
Contact
yangruixue2020@163.com
+86-10-81992130

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion